Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $215M
Founded date: 2014
Investors 8
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2020 | Series D | $215M | - |
Mentions in press and media 10
| Date | Title | Description |
| 17.11.2021 | Chugai Pharmaceutical : Atea Announces Update on Collaboration with Roche for AT-527 | Atea Announces Update on Collaboration with Roche for AT-527 TOKYO, November 17, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Atea issued a press release on its collaboration with Roche for the investigational oral COV... |
| 12.11.2021 | Atea Announces Update of Clinical Studies Evaluating AT-527 for COVID-19 in the Outpatient Setting | November 12, 2021 Name of listed company: Chugai Pharmaceutical Co., Ltd. Code number: 4519 (1st Section of Tokyo Stock Exchange) Head office: 1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo President & CEO: Osamu Okuda Inquiries to: Tos... |
| 20.10.2021 | Chugai Pharmaceutical : Atea Announces Update and Topline Results of MOONSONG Study Evaluating AT-527 for COVID-19 in the Outpatient Setting | Atea Announces Update and Topline Results of MOONSONG Study Evaluating AT-527 for COVID-19 in the Outpatient Setting TOKYO, October 20, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Atea issued a press release on Octobe... |
| 19.10.2021 | Atea Pharma Stumbles in Race for a Covid Pill. The Stock Is Down 64%. | Atea Pharma ceuticals, the company behind one of the most-watched oral Covid-19 antiviral programs, delivered a disappointing failure on Tuesday, saying the pill didn’t reduce the viral load of patients with mild or moderate cases in a Phas... |
| 11.10.2021 | The first-ever COVID-19 pill may be just weeks away. A handful of other pills, inhalers, and nasal sprays also show promise. | A man holds a capsule. Photographer, Basak Gurbuz Derman/Getty Images Treating COVID-19 could be simpler soon, thanks to the next generation of treatments. These could come in the form of pills, nasal sprays, or inhalers. On Monday, Merck a... |
| 22.10.2020 | Roche wades deeper into Covid-19 fight, inking antiviral pact with $350M cash following Regeneron deal | Roche is making its first bet on an antiviral against Covid-19 in style, shelling out $350 million in cash to grab ex-US rights. The drug comes from Atea Pharmaceuticals, the 7-year-old biotech created by Pharmasset co-founder J... |
| 21.05.2020 | Ally Bridge Portfolio News – Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing | BOSTON, May 20, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Ser... |
| 20.05.2020 | Atea raises $215M to support midphase COVID-19 antiviral trial | Bain Capital Life Sciences has powered Atea Pharmaceuticals to a $215 million financing round. The series D sets Atea up to run a phase 2 trial of its oral purine nucleotide prodrug in people hospitalized with moderate cases of COVID-19. Sp... |
| 20.05.2020 | Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing | - |
| - | Here are the 15 highest-paid CEOs in biopharma, bringing in paychecks of at least $25 million in 2021 — with 2 making over $100 million | This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider got exclusive data on the highest-paid CEOs in the pharma and biotech industries in 2021. The research firm MyLogIQ identified 15 C... |